Introduction
The profound motor and behavioral action of cannabinoids are thought to be mainly mediated by CB 1 receptors (Howlett et al., 1990; Compton et al., 1996) . Indeed, CB 1 receptors are present in high density in the basal ganglia (Herkenham et al., , 1991 Mailleux and Vanderhaeghen, 1992) . The existence of CB 1 receptor mRNA transcripts in the caudate-putamen (Mailleux and Vanderhaeghen, 1992; Julian et al., 2003) suggests that CB 1 receptors are synthesized in striatal GABAergic efferent neurons (for review, see Romero et al., 2002) .
The therapeutic role of the endocannabinoid system is now widely recognized (for review, see Di Marzo et al., 2004) . Drugs acting at CB 1 receptors have therapeutic potential in Huntington's and Parkinson's diseases (for review, see Romero et al., 2002; Brotchie, 2003; Lastres-Becker et al., 2003; van der Stelt and Di Marzo, 2003) . Namely, both endocannabinoid levels and CB 1 receptor density are selectively altered in the basal ganglia in animal models of Parkinson's and Huntington's diseases (Di Marzo et al., 2000c; Romero et al., 2000; Lastres-Becker et al., 2001a,b; Gubellini et al., 2002; Maccarrone et al., 2003) and in parkinsonian patients (Lastres-Becker et al., 2001a; Hurley et al., 2003) . Furthermore, cannabinoids reduce levodopa-induced dyskinesia (Sieradzan et al., 2001; Ferrer et al., 2003) .
The mechanisms of cannabinoid action in the striatum are still unclear. Cannabinoids, applied in vivo, increase striatal dopaminergic transmission (Malone and Taylor, 1999; Melis et al., 2000) , likely via increasing the neuronal firing in the ventral tegmental area (Robbe et al., 2001 ) and in the substantia nigra. However, in vitro, they directly did not affect the release of dopamine (Szabo et al., 1999) . Cannabinoids depress both GABAergic (Szabo et al., 1998) and glutamatergic [caudate-putamen (Gerdeman and Lovinger, 2001; Huang et al., 2001; Gerdeman et al., 2002; Brown et al., 2003; Ronesi et al., 2004) , nucleus accumbens (Robbe et al., 2001 (Robbe et al., , 2002 ] synaptic currents through presynaptic CB 1 receptor activation. However, we (Köfalvi et al., 2003) and others (Hájos et al., 2001) have recently shown that cannabinoids still decrease glutamate release in the hippocampus in the CB 1 Ϫ/Ϫ mouse. Moreover, the endocannabinoid/endovanilloid agonist anandamide in the CB 1 Ϫ/Ϫ mice and the synthetic cannabinoid/vanilloid agonist arvanil in the wild-type mice depress spontaneous activity and cause catalepsy in a manner independent from CB 1 and TRPV 1 receptor activation (Di Marzo et al., 2000a,b) . Furthermore, both anandamide and the synthetic cannabinoid agonist (R)-(ϩ)-[2, 3-dihydro-5-methyl(-3[(4-morpholinyl) methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate salt (WIN55212-2) stimulate GTP␥S binding in brain membranes from CB 1 Ϫ/Ϫ mice, although not in the basal ganglia (Di Marzo et al., 2000b; Breivogel et al., 2001; Monory et al., 2002) . All of these observations support the notion that there are additional receptors for these ligands (Pertwee, 2004) . Therefore, it is important to determine whether CB 1 receptors are the only receptors responsible for the presynaptic effect of cannabinoids in the striatum.
Thus, our goals were (1) to analyze the distribution of CB 1 receptors to define the colocalization of CB 1 immunoreactivity with markers of different types of nerve terminals and (2) to perform a pharmacological analysis of the effect of cannabinoids on the three main striatal neurotransmitters.
Materials and Methods

Animals
All studies were conducted in accordance with the principles and procedures outlined in the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the local Animal Care Committees of our institutes. CB 1 receptor homozygote knock-out mice were generated as described previously (Ledent et al., 1999) . The genotype of the mice was tested by the conventional PCR technique on genomic DNA obtained from the tails of experimental animals immediately after the experiments.
Localization of the CB 1 receptor in rat striatal nerve terminals
Subsynaptic distribution of CB 1 receptor in the rat striatum. The solubilization of the presynaptic active zone and the extrasynaptic and postsynaptic fractions from rat striatal synaptosomes was performed according to the method described previously (Phillips et al., 2001) , with minor modifications. We confirmed previously that this subsynaptic fractionation method allows a Ͼ90% effective separation of markers of the presynaptic active zone (syntaxin and synaptosomeassociated protein of 25 kDa), postsynaptic density [postsynaptic density-95 (PSD-95) and NMDA receptor subunit 1], and extrasynaptic (synaptophysin) markers and can be used to assess the subsynaptic distribution of metabotropic receptors (Rebola et al., 2003) .
Briefly, striata from 12 male Wistar rats were homogenized at 4°C with a Teflon-glass homogenizer in 15 ml of isolation solution [0.32 M sucrose, 0.1 mM CaCl 2 , 1 mM MgCl 2 , and 0.1 mM phenylmethylsulfonyl fluoride (PMSF)]. The concentration of sucrose was raised to 1.25 M by the addition of 75 ml of 2 M sucrose and 30 ml of 0.1 mM CaCl 2 , and the suspension was divided in 10 ultracentrifuge tubes. The homogenate was overlaid with 8 ml of 1.0 M sucrose, 0.1 mM CaCl 2 , and 5 ml of homogenization solution and centrifuged at 100,000 ϫ g for 3 h at 4°C. Synaptosomes were collected at the 1.25/1.0 M sucrose interface, diluted 1:10 in cold 0.32 M sucrose with 0.1 mM CaCl 2 , and pelleted (15,000 ϫ g for 30 min at 4°C). Pellets were resuspended in 1 ml of 0.32 M sucrose with 0.1 mM CaCl 2 , and a small sample was taken for gel electrophoresis. The solubilization procedure was also performed as described by Phillips et al. (2001) , with minor modifications. Briefly, synaptosomal suspension was diluted 1:10 with cold 0.1 mM CaCl 2 , and an equal volume of 2ϫ solubilization buffer (2% Triton X-100 and 40 mM Tris, pH 6.0) was added to the suspension. The membranes were incubated for 30 min on ice with mild agitation, and the insoluble material (synaptic junctions) was pelleted (40,000 ϫ g for 30 min at 4°C). The supernatant (extrasynaptic fraction) was decanted, and the proteins were precipitated with 6 vol of acetone at 20°C and recovered by centrifugation (18,000 ϫ g for 30 min at 15°C). The synaptic junctions pellet was washed with solubilization buffer, pH 6.0, resuspended in 10 ml of 1% Triton X-100 and 20 mM Tris, pH 8.0, incubated for 30 min on ice with mild agitation, and centrifuged (40,000 ϫ g for 30 min at 4°C), and the supernatant (presynaptic fraction) was processed as described above. PMSF (1 mM) was added to the suspension in all extraction steps. The pellets from the supernatants and the final insoluble pellet (postsynaptic fraction) were solubilized in 5% SDS, the protein concentration was determined by the bicinchoninic acid protein assay, and the samples were added to a 1/6 vol of 6ϫ SDS-PAGE sample buffer before freezing at Ϫ20°C.
Western blot analysis was performed using 30 g of each protein fraction, obtained as described above, which were loaded onto a 7.5% SDS-PAGE gel and then transferred onto polyvinylidene difluoride membranes. Membranes were blocked for 1 h at room temperature in 5% low-fat milk in Tris-buffered saline medium with 0.1% Tween 20 (Merck-Schuchardt, Munich, Germany). The membranes were probed with a rabbit antibody raised against the last 15 aa of the C-terminal of the rat CB 1 receptor (1:5000) overnight at 4°C. Detection was performed using the alkaline phosphatase-conjugated secondary antibody of goat anti-rabbit IgG (1:20,000; Amersham Biosciences, Little Chalfont, UK). Immunoblots were visualized using the enhanced chemifluorescence detection reagent (Amersham Biosciences). The specificity of CB 1 receptor antibody has been confirmed by the laboratory of origin and by the lack of immunostaining in the CB 1 receptor knock-out mice (Katona et al., 2001) .
Localization of CB 1 receptor immunoreactivity in different nerve terminals of the rat and mouse striatum. For immunochemical analysis, synaptosomes from striata of male Wistar rats (6 weeks old) and male CD-1 mice (see above) were obtained through a discontinuous Percoll gradient, following the procedure described by Díaz-Hernandez et al. (2002) , with minor modifications. Striata were homogenized in 0.25 M sucrose and 5 mM N-[tris [hydroxymethyl] methyl]-2-aminoethanesulfonic acid (TES), pH 7.4. The homogenate was spun for 3 min at 2000 ϫ g at 4°C, and the resulting supernatant was spun again at 9500 ϫ g for 13 min. Then the pellets were resuspended in 8 ml of 0.25 M sucrose and 5 mM TES, pH 7.4. Two milliliters of this synaptosomal suspension were placed onto 3 ml of Percoll discontinuous gradients containing 0.32 M sucrose, 1 mM EDTA, 0.25 mM dithiothreitol, and 3, 10, or 23% Percoll, pH 7.4. The gradients were centrifuged at 25,000 ϫ g for 11 min at 4°C. Synaptosomes were collected between the 10 and 23% Percoll bands and diluted in 15 ml of HEPES-buffered medium (in mM: 140 NaCl, 5 KCl, 5 NaHCO 3 , 1.2 NaH 2 PO 4 , 1 MgCl 2 , 10 glucose, and 10 HEPES, pH 7.4).
The striatal synaptosomes were placed onto coverslips previously coated with poly-L-lysine, fixed with 4% paraformaldehyde for 15 min, and washed twice with PBS (in mM: 140 NaCl, 3 KCl, 20 NaH 2 PO 4 , 15 KH 2 PO 4 , pH 7.4). Permeabilization was performed in PBS containing 0.2% Triton X-100 for 10 min, and afterward the synaptosomes were incubated in PBS medium containing 3% bovine serum albumin (BSA) and 5% normal rat serum for 1 h. The synaptosomes were then washed twice with PBS and incubated with rabbit anti-CB 1 receptor and chicken anti-vesicular glutamate transporter (VGLUT)-1 (1:5000; Alpha Diagnostic, San Antonio, TX) and guinea pig anti-VGLUT-2 (1:5000; Chemicon, Temecula, CA), or guinea pig anti-vesicular GABA transporter (VGAT; 1:1000; Calbiochem, Darmstadt, Germany), or mouse antityrosine hydroxylase (Tyr-OH; 1:1000; Chemicon), or mouse anti- 
Release experiments
Four male Wistar rats (140 -160 g; Gedeon Richter, Budapest, Hungary) or five male young adult mice (20 -22 g) were decapitated under ether anesthesia, and the brains were quickly put into ice-cold Krebs' solution of the following composition (in mM): 115 NaCl, 4.7 KCl, 1.2 KH 2 PO 4 , 1.2 MgSO 4 , 2.5 CaCl 2 , 25 NaHCO 3 , and 10 glucose, oxygenated with 95% O 2 and 5% CO 2 , pH 7.4. All striata were dissected rapidly and used for slice or synaptosomal experiments. For slice experiments, 400 m slices were cut with a McIlwain tissue chopper (Bachofer, Reutlingen, Germany) and used for incubation (see below). A synaptosomal fraction of the striatum was prepared with slight modifications of the technique described previously (Cunha and Ribeiro, 2000; Köfalvi et al., 2003) . The removed striata were homogenized in ice-cold 0.32 M sucrose solution (containing 1 mM EDTA, 1 mg/ml BSA, and 5 mM HEPES, pH 7.4) at 4°C and centrifuged at 2000 ϫ g for 10 min. The supernatant was centrifuged at 13,000 ϫ g for 12 min. The pellet was resuspended in ice-cold 45% (v/v) Percoll in Krebs' solution, pH 7.4, and centrifuged at 13,000 ϫ g for 2 min to eliminate free mitochondria and glial debris. The top layer was washed twice at 13,000 ϫ g for 2 min in oxygenated Krebs' solution at 4°C.
[ 3 H]GABA and [ 3 H] dopamine release experiments from striatal slices. The experiments were performed as described previously (Milusheva et al., 1996; Köfalvi et al., 2000) , with slight modifications. Briefly, slices were incubated for 30 min at 37°C in the presence of After termination of the 1 h presuperfusion period, 3 min samples were collected for tritium assay (sample collection period). At 6 and 36 min after the start of the sample collection period, the release of [ 3 H] transmitters was stimulated twice (EFS 1 and EFS 2 ) with electrical field stimulation (at 40 V, 2 Hz, 1 ms, 360 bipolar, square-wave pulses; except where noted otherwise), delivered by a Grass S88 Stimulator (Grass Medical Instruments, Quincy, MA) via a pair of platinum ring electrodes. Throughout the experiments, the temperature was maintained at 37°C. All drugs were introduced 20 min before the first or the second electrical field stimulation, as indicated later.
[ 3 H]Glutamate release experiments from striatal synaptosomes. The experiments were performed with slight modifications of our previous study (Köfalvi et al., 2003) . The synaptosomes were diluted to 1.5 ml with Krebs' solution and equilibrated with careful oxygenation (95% O 2 and 5% CO 2 ) at 37°C for 5 min, after which 4 Ci of [ 3 H]glutamate (Amersham Biosciences) was added to the synaptosomes for 5 min. All solutions contained the GABA-T/GAD inhibitor aminooxyacetic acid (200 M). Ninety-microliter aliquots (ϳ610 g of protein) of the preloaded synaptosomes were transferred into 100 l volume superfusion chambers of a 12-channel suprafusion system (Brandel, Gaithersburg, MD), trapped between two layers of Whatman (Maidstone, UK) GF/C filters, and superfused continuously at a rate of 0.5 ml/min until the end of the experiment. At 12 min after the start of the 45 min washout period, D-aspartate (50 M; Sigma) was administered for 5 min to effectively reduce the Ca 2ϩ -independent release of glutamate evoked by high K ϩ (Terrian et al., 1991; Köfalvi et al., 2003) . After termination of the 45 min washout, 3 min samples were collected for liquid scintillation assay. All experimental periods were performed at 37°C. At 6 and 36 min after the start of the sample collection period, the release of [ 3 H]glutamate was stimulated twice (S K1 and S K2 ) with 25 mM K ϩ (isomolar substitution of Na ϩ by K ϩ in the buffer) for 3 min. The antagonists were given 20 min before S K1 (except where noted otherwise), whereas the agonists were given 20 min before S K2 , both being present until the end of the experiments.
Validation of transmitter release. The tritium distribution in the effluent, under basal condition and stimulation, was analyzed by HPLC with fluorometric detection as described previously (Nakai et al., 1999) . The majority of tritium represented the respective transmitters (GABA, glutamate, and dopamine), according to our previous findings. Tetrodotoxin (TTX) (1 M; n ϭ 4 in all cases) strongly inhibited the release of 3 H]glutamate into synaptosomes was investigated in the absence and presence of cannabinoid ligands. To study the uptake of GABA or DA, the incubation with the isotope was performed as described above, at 37°C. After a 30 min incubation, the slices were rinsed three times, weighed, and homogenized, and the tritium content of the homogenates was assayed and expressed in milligrams of tissue weight. For [
3 H]glutamate uptake experiments, after a 5 min equilibration with continuous gassing at 37°C, 50 l aliquots of the preparation was transferred into 450 l of incubation solution containing the drugs or their vehicle (vehicle control). After a 20 min incubation at 37°C, the uptake was terminated on ice, and the synaptosomes were washed three times at 15,000 ϫ g for 5 min, diluted and sonicated in 10% trichloroacetic acid, and assayed for tritium. The uptake of glutamate was strongly dependent on sodium (8.0 Ϯ 0.4% of control; n ϭ 6; p Ͻ 0.001 when sodium was replaced by choline chloride) and on temperature (12 Ϯ 2.3% of control; n ϭ 6; p Ͻ 0.01 at 12°C).
Radioactivity assay and calculations. The radioactivity released from the preparations was measured with a Packard (Canberra, Australia) 1900 Tricarb liquid scintillation spectrometer, equipped with Dynamic Color Corrected DPM Option providing absolute activity (DPM) calculation and correction for different color quenching. The release of the transmitters was calculated as the percentage of the amount of radioactivity in the tissue at the sample collection time [fractional release (FR%)]. The tissue/synaptosomal tritium uptake was determined as the sum release plus the tissue/synaptosomal content after the experiment. The stimulation-evoked release of the transmitters was calculated by the area-under-the-curve method. All data represent mean Ϯ SEM of n Ն 4 observations. EC 50 values were calculated by fitting the data to sigmoidal logistic equations using the Prism 4.00 (Graph Pad, San Diego, CA) program. When the decrease in baseline was calculated, the tritium content of the last sample before the second stimulus was expressed as the percentage of the tritium content of the last sample before the first stimulus. Statistical significance was calculated by Student's t test or ANOVA, followed by Bonferroni's test for selected pairs of columns, as appropriate, and p Ͻ 0.05 was accepted as significant change.
Drugs. TTX, Na 2 CNQX, AP-5, and bicuculline methobromide (all from Sigma) were dissolved in distilled water. WIN55212-2 and S(Ϫ)- [2,3-dihydro-5-methyl-3-[(4-morpholinyl) 
were dissolved in ethanol. The maximum concentrations of vehicles used had no significant effect on the release of the transmitters.
Results
Subsynaptic distribution of CB 1 receptor in the rat striatum The method of solubilization of subsynaptic fractions allows the antibodies to access the presynaptic active zone and the postsynaptic density, which provided the opportunity to explore the subsynaptic CB 1 receptor distribution. This technique appears to be far more sensitive than classical immunogold electron microscopy for determining the localization of synaptic receptors (Phillips et al., 2001; Rebola et al., 2003) . Western blot analyses of the subsynaptic fractions showed significant CB 1 immunoreactivity in all fractions. The total amount of synaptic CB 1 receptors from the initial fraction is denoted as "whole" in Figure 1 , representing 100%. After fractionation, we found nearly 23% of the synaptic CB 1 receptors in the presynaptic active zone (Fig. 1, pre) and nearly 30% of them in the postsynaptic density (Fig. 1, post) , where electron microscopy generally cannot localize them, likely because of antibody accessibility problems. The rest of the CB 1 receptor immunoreactivity was found in the extrasynaptic fraction of presynaptic and postsynaptic sides ( Fig. 1 A, B , extra).
Localization of CB 1 receptor immunoreactivity in different nerve terminals of the rat striatum
The protocol for separation of nerve terminals is designed to exclude contamination by postsynaptic elements. Nonetheless, we stained the nerve terminals for PSD-95, a postsynaptic marker protein, and observed a very low (ϳ0.01%) number of PSD-95-positive elements in synaptophysin-costained plates of synaptosomes (data not shown), establishing the specificity of the isolation procedure. Figure 2 , A and B, illustrates that a high percentage (60%) of nerve terminals (identified by synaptophysin) display CB 1 receptor immunoreactivity, according to the well known strong CB 1 receptor expression in the striatum (Herkenham et al., , 1991 Mailleux and Vanderhaeghen, 1992) . Approximately 2000 synaptosomes were counted for each marker [i.e., VGAT (for GABAergic axon terminals; rat), VGLUT-1 and VGLUT-2 (for glutamatergic axon terminals; rat and mouse), and Tyr-OH (for catecholaminergic axon terminals; rat)] and for the CB 1 receptor. The strong CB 1 receptor density in GABAergic terminals is in agreement with previous morphological data (for review, see van der Stelt and Di Marzo, 2003) . With respect to glutamatergic terminals, the presence of CB 1 receptors was expected based on electrophysiological observations (Gerdeman and Lovinger, 2001; Huang et al., 2001; Brown et al., 2003; Ronesi et al., 2004) . Only a low percentage of CB 1 receptor immunoreactivity colocalized with Tyr-OH immunoreactivity, which is a marker for both noradrenergic and dopaminergic terminals.
[
3 H]GABA release from rat striatal slices After the 1 h washout period, the basal [ 3 H]GABA efflux amounted to 0.192 Ϯ 0.010 FR% (n ϭ 10), similar to that in the hippocampus (Katona et al., 1999; Köfalvi et al., 2000) . The [ 3 H]GABA release evoked by the first electrical stimulation (40 V, 2 Hz, 1 ms, 360 shocks, EFS 1 ) was 0.221 Ϯ 0.041 FR%, whereas the EFS 2 /EFS 1 value was 0.958 Ϯ 0.091 (Fig. 3A-C) . Although the nonselective cannabinoid agonist WIN55212-2 (0.01-1 M) failed to affect the basal (resting) release, it concentration dependently and significantly diminished the evoked [
3 H]GABA release, with an EC 50 value of 32 nM ( Fig. 3 A, B) . The maximal effect was obtained at 1 M (42% inhibition; n ϭ 13; p Ͻ 0.01). ACEA, the highly CB 1 receptor-selective agonist (1 M), also inhibited the evoked [
3 H]GABA release by 27% (n ϭ 8; p Ͻ 0.05) (Fig. 3B ). AM251 (1 M; n ϭ 6) and SR141716A (1 M; n ϭ 4), the two CB 1 receptor-selective antagonists introduced before the first stimu- Figure 1 . CB 1 receptors are located mainly extrasynaptically but also at the presynaptic active zone and at the postsynaptic density of rat striatal nerve terminals. A, Western blot (representative of 4 similar blots from different groups of animals) comparing CB 1 receptor immunoreactivity, corresponding to the 53 kDa band, in a fraction enriched in the presynaptic active zone (pre), in the postsynaptic density (post), in the nerve terminals portion outside the active zone (extra), and in the initial synaptosomal fraction (whole), from which fractionation was performed. These fractions were obtained by pH fractionation, after solubilization of purified striatal nerve terminals as described in Materials and Methods. Thirty micrograms of protein of each fraction were applied into the SDS-PAGE gel, and a CB 1 antibody was used at a 1:5000 dilution. B, Average distribution of CB 1 receptor immunoreactivity in subsynaptic compartments. The CB 1 receptor density was higher in the extrasynaptic fraction but was also present, to a lesser extent, in the presynaptic active zone and in the postsynaptic density.
lation, prevented the inhibition by WIN55212-2 (1 M), whereas they alone had no effect on the release (Fig. 3C) . The ionotropic glutamate receptor antagonists AP-5 (50 M) and CNQX (10 M), all introduced before the first stimulation, did not affect the action of WIN55212-2 (1 M) on the evoked [ 3 H]GABA release (n ϭ 8; p Ͻ 0.05) (Fig. 3C) . . CB 1 receptors are present on GABAergic (from rat) and glutamatergic (from rat and mouse) and, to a lesser extent, on catecholaminergic (from rat) terminals. A, Representative double-labeling images of anti-CB 1 receptor (CB 1 R) with anti-synaptophysin (marker of all nerve terminals), anti-VGAT (specific marker of GABAergic nerve terminals), anti-VGLUT-1 and anti-VGLUT-2 (specific markers of glutamatergic nerve terminals), and anti-Tyr-OH (specific marker of catecholaminergic nerve terminals). B, A summary of the extent of CB 1 receptor colocalization with the specific markers of each type of nerve terminal (mean Ϯ SEM of n ϭ 4 -6 plates) after counting ϳ2000 terminals for each marker.
The effect of WIN55212-2 (1 and 30 M) was tested on the uptake of [ 3 H]GABA, to determine whether the decrease in the evoked release is attributable to increased uptake. After the 30 min incubation, the tritium uptake into the slices amounted to 27,085 Ϯ 6741 DPM/mg tissue [vehicle control (CTRL), n ϭ 10], which was unaltered in the presence of 1 M WIN55212-2 (n ϭ 6) (Fig. 3B ). The cannabinoid agonist had no effect on the uptake of [ 3 H]GABA even at 6 M (data not shown) and 30 M, which is supramaximal for the CB 1 receptor.
[ 3 H]DA release experiments from slices After the 1 h washout period, the basal [ 3 H]DA efflux amounted to 0.551 Ϯ 0.040 FR% (n ϭ 10), similar to that found in our previous study (Milusheva et al., 1996) . The same electrical field stimulation parameters were used as to evoke [ 3 H]GABA release. The first stimulation-evoked release (EFS 1 ) was 2.794 Ϯ 0.262 FR%, and the EFS 2 /EFS 1 value was 0.757 Ϯ 0.061 (Fig. 4 A-C) . WIN55212-2 (0.3-10 M) and CP55940 (1-10 M) did not significantly affect either the resting or the evoked [ 3 H]DA release (Fig. 4 A, B) . To reveal whether a cannabinoid effect would appear at a different stimulation frequency, we also stimulated the slices at 0.5 Hz (EFS 1 , 2.385 Ϯ 0.400; EFS 2 /EFS 1 , 0.822 Ϯ 0.108; n ϭ 6) as well as at 10 Hz (EFS 1 , 1.719 Ϯ 0.266; EFS 2 /EFS 1 , 0.810 Ϯ 0.055; n ϭ 4). WIN55212-2 (1 M; n ϭ 6 and 4) did not modify the evoked release of [ 3 H]DA at any of the frequencies tested. It is possible that the effect of the cannabinoids was hidden because of simultaneous activation of inhibitory and/or excitatory neurotransmission by field stimulation in the intact slice. Thus, we challenged the [ 3 H]DA release with WIN55212-2 (1 M) in the presence of the ionotropic glutamate receptor antagonists AP-5 (50 M) and CNQX (10 M) and the GABA A receptor antagonist bicuculline (20 M). However, no alteration of the evoked and resting [
3 H]DA release by WIN55212-2 was observed under this condition (Fig. 4C) . CB 1 receptor activation may lead to the production of nitric oxide (for review, see Howlett and Mukhopadhyay, 2000) , which can interact with the release of dopamine in the striatum (Kiss et al., 2004) . However, WIN55212-2 (1 M) had no effect on the release of dopamine in the presence of N--nitro-L-arginine methyl ester (L-NAME) (100 M), the watersoluble nitric oxide synthase inhibitor (Fig. 4C) . D 2 and CB 1 receptors can form heterodimers. Coactivation of this chimeric receptor by cannabinoids and dopamine increases cAMP accumulation (Glass and Felder, 1997; Jarrahian et al., 2004 ). This could also mask an inhibitory response mediated by lone CB 1 receptors. But WIN55212-2 (1 M) did not change the evoked or resting [
3 H]DA release in the presence of the D 2 receptor antagonist sulpiride (3 M) (Fig. 4C ). Next, we tested whether the CB 1 receptors were already active (by constitutive activity or by endocannabinoids). The CB 1 -selective antagonist SR141716A (at 10 M, a concentration supramaximal to antagonize the CB 1 receptors), introduced after the first stimulation, altered neither the resting nor the evoked release of dopamine (Fig. 4C) . Finally, WIN55212-2 at 6 M did not modify the uptake of dopamine, which amounted to 15,776 Ϯ 4745 DPM/mg tissue (vehicle CTRL, n ϭ 6) (Fig. 4 B) . Thus, the lack of change in dopamine release could not have been caused by simultaneous reductions in uptake and release. Fig. 3 A, B) . Note that WIN55212-2 also did not affect release if the frequency of stimulation was four times lower or five times higher (see Results). C, The lack of modulation by WIN55212-2 (expressed with the EFS 2 /EFS 1 ratio) is not attributable to the presence of facilitatory or inhibitory polysynaptic mechanisms, because the blockade of ionotropic glutamate receptors by CNQX (10 M) and AP-5 (50 M) and by the GABA A antagonist bicuculline (20 M), respectively, did not reveal any WIN55212-2-mediated modulation, nor did the blockade of nitric oxide synthase by L-NAME (100 M). Activation of CB 1 receptors by endogenous cannabinoids does not explain the lack of WIN55212-2 effect because the selective CB 1 receptor antagonist SR141716A (10 M) applied 20 min before EFS 2 had no effect on the second stimulation-evoked release of (Köfalvi et al., 2003) (Fig. 5A-C) 5A-C) . It is noteworthy that WIN55212-3, the enantiomer of WIN55212-2 being inactive at the CB 1 receptor, had no significant effect (n ϭ 4) (Fig. 5B ). This enantiomer was applied at 6 M, at which the original compound exerted maximal inhibition. In our previous study (Köfalvi et al., 2003) , we found concentration-dependent inhibition of the 25 mM K
]glutamate release by SR141716A, the CB 1 -selective antagonist in the hippocampus. A similar inhibition also occurs in striatal synaptosomes (0.6 -30 M; EC 50 , 3.01 M; maximal effect, 45.9%). In addition, a structurally related CB 1 antagonist, AM251 (0.6 -30 M; EC 50 , 3.94 M; maximal effect, 57.0%), also decreases glutamate release (Fig. 5B) . This effect, which is unique for the release of glutamate, makes the antagonists as potent and effective glutamate release inhibitors as WIN55212-2, the agonist.
Next, we tested the effect of WIN55212-2 and CP55940 at the concentrations that had evoked the maximal effect, in the presence of SR141716A and AM251, the CB 1 -selective antagonists, at a concentration that did not decrease glutamate release (1 M). SR141716A partially reversed the inhibition of CP55940 (3 M) and of WIN55212-2 (6 M), but the effect of agonists remained significant. However, their effects on the evoked release were completely prevented by AM251 (Fig. 5C ).
WIN55212-2 and AM251 at the low micromolar range inhibit veratridine (i.e., sodium channel activation)-evoked glutamate release from whole-brain synaptosomes by direct, competitive blockade of voltage-dependent Na ϩ channels (Nicholson et al., 2003; Liao et al., 2004 ). In our model, as expected, the 25 mM K ϩ -evoked [ 3 H]glutamate release was not TTX (1 M) (i.e., voltage-gated sodium channel) dependent (Fig. 5C) ; therefore, the effect of the cannabinoid ligands was independent of sodium channel blockade.
WIN55212-2 slightly but concentration dependently attenuated the resting [ 3 H]glutamate outflow, with a maximal effect of 24% at 6 M (n ϭ 6; p Ͻ 0.05) (Fig. 5A) . The same was observed with CP55940 (21% at 10 M; n ϭ 6; p Ͻ 0.05), whereas ⌬ 9 -THC was devoid of any effect on the resting [ 3 H]glutamate outflow at the concentrations tested. This suggests that some cannabinoid ligands might affect glutamate transporters independently of activation of the CB 1 receptor. To test this hypothesis, we challenged the uptake of glutamate by WIN55212-2. The [ 3 H]glutamate uptake into striatal synaptosomes amounted to 571,127 Ϯ 9282 DPM/50 l (ϳ340 g of protein; n ϭ 24). WIN55212-2 (6 M) concentration dependently attenuated the uptake of [ 3 H]glutamate with the EC 50 value of 2.62 M (Fig. 5D ). SR141716A (1 M) alone had no significant effect on the uptake and did not reverse the uptake inhibitory action of WIN55212-2 (Fig. 5D ). AM251 concentration dependently attenuated the uptake of [ 3 H]glutamate, and again 1 M AM251 fully prevented the effect of WIN55212-2. WIN55212-3, the enantiomer of WIN55212-2 inactive at the CB 1 receptor, had the same efficacy to attenuate [ 3 H]glutamate uptake (i.e., the action of cannabinoids on [ 3 H]glutamate uptake might not be CB 1 receptor mediated) (Fig. 5D ).
Localization of CB 1 receptor expression on glutamatergic nerve terminals of wild-type mouse striatum
Because the pharmacological profile of the cannabinoid receptor underlying the attenuation of glutamate efflux was not entirely identical to that responsible for the reduction of [ 3 H]GABA release, we also explored the localization and function of CB 1 receptors in striatal nerve terminals of wild-type and CB 1 Ϫ/Ϫ mice. Overall, 1684 immunopositive nerve terminals from three wild-type animals, littermates of the CB 1 Ϫ/Ϫ mice, were counted. Interestingly, 78.8 Ϯ 8.5% of VGLUT-1-and VGLUT-2-positive nerve terminals were . The diagrams show that (in order of potency) CP55940, ⌬ 9 -THC, SR141716A, WIN55212-2, and AM251 (i.e., both agonists and antagonists of the CB 1 receptor) concentration dependently inhibited the evoked release of [ 3 H]glutamate. WIN55212-2 (6 M) and AM251 (30 M) displayed the greatest efficacy. WIN55212-3, the enantiomer inactive at the CB 1 receptor, had no effect at 6 M. C, SR141716A (SR) attenuated by only one-third the effect of WIN55212-2 (WIN) or CP55940 (CP), but AM251 (AM) fully prevented the action of WIN55212-2 and CP55940. As expected, the evoked [ 3 H]glutamate release was not sodium channel (i.e., TTX) dependent. D, WIN55212-2 inhibited the uptake of [ 3 H]glutamate as well, which was prevented only by AM251. However, the effect of WIN55212-2 was nonstereoselective (i.e., non-CB 1 receptor-mediated). AM251 more potently and effectively inhibited the uptake of [ 3 H]glutamate than WIN55212-2. *p Ͻ 0.05; **p Ͻ 0.01. Only one point per ligand was marked for significance for the sake of simplicity. n Ն 6 for all data points. CTRL, Control.
endowed with CB 1 immunoreactivity, indicating an ϳ40% greater colocalization than in the rat ( Fig. 2A,B) . Figure 6 A. Although the resting and evoked [ 3 H]glutamate efflux were similar in the rat and in the wild-type mouse, the basal release was slightly and significantly higher, whereas the evoked release was slightly and significantly lower in the CB 1 Ϫ/Ϫ mouse. Interestingly, WIN55212-2 appeared to be less potent and efficacious to inhibit the release of [ 3 H]glutamate in the wild-type mice (Fig.  6C ) than in the rat striatum or in the mouse hippocampus (Köfalvi et al., 2003) . In contrast, CP55940 inhibited the evoked release by 26% already at 3 M. AM251 (1 M) applied 20 min before the first stimulation significantly decreased the S K2 /S K1 ratio in wild-type mice, and in the presence of AM251, WIN55212-2 (20 M) did not further inhibit the evoked release of [ 3 H]glutamate (Fig. 6C) . Nevertheless, the inhibitory effect of both cannabinoid agonists, as well as that of AM251, persisted in the CB 1 Ϫ/Ϫ mouse (Fig. 6D) . Furthermore, AM251 occluded the effect of WIN55212-2 in the CB 1 receptor knock-out mice. This is in contrast to the hippocampus, where another CB 1 receptor-selective antagonist, SR141716A, applied at 1-5 M did not prevent the inhibition produced by agonists (Köfalvi et al., 2003) . WIN55212-2 (20 M; 24%; n ϭ 6; p Ͻ 0.01) and CP55940 (3 M; 17%; n ϭ 6; p Ͻ 0.01) also significantly inhibited the basal release of [ (Fig. 6B) . For the sake of comprehension, the effect of cannabinoid agonists and antagonists on the uptake and the stimulation-evoked release of [ 3 H]glutamate is summarized in Table 1 .
Discussion
Activation of CB 1 receptors attenuates neuronal activity by presynaptic inhibition of neurotransmitter release and postsynaptic hyperpolarization (for review, see Freund et al., 2003) . We now used a highly sensitive immunochemical method that allows determining the quantitative distribution of CB 1 receptors among subsynaptic elements in isolated nerve terminals. Our novel finding (i.e., the localization of CB 1 receptors in the presynaptic active zone) facilitates our understanding of how CB 1 receptors likely attenuate neurotransmitter release via inhibition of active zone molecular targets (i.e., of N-and P-type calcium channels and release machinery functions) (for review, see Jarvis and Zamponi, 2001) . The CB 1 receptor immunoreactivity, found extrasynaptically, which may indicate recycling and/or newly synthesized pools of the CB 1 receptors, is concordant with our previous electron microscopy findings in the hippocampus, where presynaptic CB 1 receptors were found primarily in extrasynaptic membranes of GABAergic boutons (Katona et al., 1999 (Katona et al., , 2000 . In the present study, receptors in the extrasynaptic fraction may comprise postsynaptic receptors outside the postsynaptic density as well, and we found CB 1 receptors also in the postsynaptic density. The presence of postsynaptic CB 1 receptors, which may control the excitability of the dendrites, is consistent with a previous immunocytochemical observation in the striatum (Rodríguez et al., 2001 ) and other functional data (Childers and Deadwyler, 1996; Bacci et al., 2004) . Together, the distribution of CB 1 receptors in the striatum is similar to that of hippocampal A 1 adenosine receptors, which were found in all subsynaptic fractions, although strategically in the active zone (Rebola et al., 2003) .
Modulation of GABAergic transmission
Our present finding (i.e., the widespread CB 1 receptor expression in GABAergic terminals) is in agreement with previous reports (Herkenham et al., , 1991 Mailleux and Vanderhaeghen, 1992; Fusco et al., 2004) . WIN55212-2 inhibited the evoked release of [
3 H]GABA with a potency and efficacy similar to those of our and others' previous findings in the hippocampus and striatum (Katona et al., 1999 (Katona et al., , 2000 Szabo et al., 1998) . Moreover, ACEA, a selective CB 1 receptor agonist, also significantly inhibited the release of GABA. The effect of WIN55212-2 was completely prevented by the CB 1 -selective antagonists AM251 and SR141716A. Similar to the hippocampus (Katona et al., 1999 (Katona et al., , 2000 , the inhibition of GABA release was not attributable to a decrease in the excitatory inputs or to an increase in reuptake. Thus, nanomolar concentrations of cannabinoid agonists inhibit the release of GABA with a pharmacological profile fully consistent with the activation of CB 1 receptors, regardless of the brain area (striatum vs hippocampus), ligands (e.g., SR141716A, AM251), and techniques (neurochemistry vs electrophysiology) used.
Modulation of dopaminergic transmission
Our present study allowed a direct visualization of CB 1 receptors for the first time on catecholaminergic terminals in the striatum. Only a small percentage of these terminals were endowed with CB 1 receptors, which corresponds to the minor expression of CB 1 receptor mRNA in the substantia nigra (Julian et al., 2003) and other dopaminergic nuclei (Matsuda et al., 1993) and suggests that cannabinoids might not modulate dopamine release directly. Accordingly, WIN55212-2 and CP55940 failed to modify the release or uptake of dopamine, even when GABAergic, glutamatergic, dopaminergic, nitrergic, and endogenous cannabinergic inputs were excluded. These data are in concordance with the results obtained by measuring endogenous dopamine levels (Szabo et al., 1999; de Lago et al., 2004) . Together, these observations do not support a major role for direct cannabinoid control of striatal dopamine release (van der Stelt and Di Marzo, 2003) .
Modulation of glutamatergic transmission
We visualized a strong CB 1 receptor expression in glutamatergic terminals, colabeled for VGLUT-1 and VGLUT-2, in the rat and mouse striatum. WIN55212-2 and CP55940 attenuated the basal [ 3 H]glutamate outflow, thought to occur mainly via membrane transporters. WIN55212-2, WIN55212-3, and AM251, but not SR141716A, also inhibited [ 3 H]glutamate uptake, even in the CB 1 Ϫ/Ϫ mouse. The possible underlying mechanisms are detailed in supplemental Figure 1 ( Ronesi et al., 2004) . The potency of WIN55212-2 and ⌬ 9 -THC were similar to those in our present study and to the EC 50 value of WIN55212-2 in our previous study in the hippocampus (3.47 M) . Furthermore, the effect of WIN55212-2 and CP55940 was prevented by the CB 1 antagonist AM251 (1 M), whereas the CB 1 -inactive enantiomer WIN55212-3 had no effect. Together, these results suggest that presynaptic CB 1 receptor activation inhibits Ca 2ϩ -dependent glutamate release in rat striatal synaptosomes.
On the other hand, a part of our present findings, in particular the persisting inhibitory effect of WIN55212-2 and CP55940 in the CB 1 Ϫ/Ϫ mice, cannot be explained by the exclusive activation of CB 1 receptors in the striatum. Indeed, cannabinoids were shown to interact with other targets to inhibit transmitter release (for review, see Di Marzo et al., 2002; De Petrocellis et al., 2004; Pertwee, 2004) . SR141716A is known to block voltage-dependent Ca 2ϩ channels and K Ca channels (EC 50 , Ϸ3-5 M) (Shen and Thayer, 1998; White and Hiley, 1998; Bukoski et al., 2002) . This can explain the inhibitory action of SR141716A and its structural analog AM251 on the K ϩ -evoked, Ca 2ϩ -dependent [ 3 H]glutamate release but not that of WIN55212-2, which stereoselectively inhibited glutamate release although it does not stereoselectively inhibit Ca 2ϩ channels. Importantly, WIN55212-2 and AM251 were recently shown to block sodium channels (Liao et al., 2004; Nicholson et al., 2003 (Fig. 5C ), therefore the effect of WIN55212-2 cannot be explained by sodium channel blockade either. Conversely, the finding that AM251 prevented the effect of cannabinoids in the CB 1 Ϫ/Ϫ mice is a clear indication for the involvement of a non-CB 1 cannabinoid receptor. However, the pharmacological phenotype of this non-CB 1 receptor seems to be very similar to the classical CB 1 receptor; therefore, we call it "CB 1 -like" receptor. Hence, although both SR141716A and AM251 are known as selective CB 1 receptor antagonists, their selectivity toward a yet unknown and uncloned receptor cannot be determined. For similar reasons, it is difficult to determine the exact contribution of CB 1 and CB 1 -like receptors in the rat and wild-type mice.
The question arises whether this CB 1 -like receptor is identical to the putative non-CB 1 cannabinoid receptors demonstrated in other studies using CB 1 Ϫ/Ϫ mouse. WIN55212-2 and anandamide in the low micromolar range inhibit glutamate release in the hippocampus of CB 1 Ϫ/Ϫ mouse (Hájos et al., 2001; Hájos and Freund, 2002a,b; Köfalvi et al., 2003) ; however, these actions were insensitive to AM251, opposite from our study. WIN55212-2 and anandamide, but not CP55940, stimulate [
35 S]GTP␥S binding in the whole-brain and cerebellar membranes (Di Marzo et al., 2000b; Breivogel et al., 2001; Monory et al., 2002) but not in the basal ganglia (Breivogel et al., 2001; Monory et al., 2002) of CB 1 Ϫ/Ϫ mice; therefore, this pathway is also unlikely to mediate the actions described in our study. On the other hand, the identity of the CB 1 -like receptor with those non-CB 1 , non-VR 1 receptors that were shown to mediate the motor depressant effect of anandamide and other vanillyl compounds (Di Marzo et al., 2000a,b) is still an open possibility, which needs additional investigation. Presumably, this CB 1 -like receptor functions regardless of the presence of CB 1 receptors in glutamatergic nerve terminals and can fully compensate the lack of CB 1 receptors in the CB 1 Ϫ/Ϫ mice, perhaps via developmental upregulation. This idea is also supported by the fact that ⌬ 9 -THC, which failed to affect locomotor activity in the CB 1 Ϫ/Ϫ mouse (Di Marzo et al., 2000b) , was less efficacious in our study, possibly because it activates mostly CB 1 receptors.
Endocannabinoid levels and CB 1 receptor expression are altered in animal models and patients of Huntington's and Parkinson's diseases (for review, see van der Stelt and Di Marzo, 2003) . This illustrates the therapeutic potential of the striatal endocannabinoid system modulation. Opposite from other previous findings (Sieradzan et al., 2001; Ferrer et al., 2003) , a recent study with cannabis (⌬ 9 -THC) did not reveal alteration of akinesia in parkinsonian patients (Carroll et al., 2004) . Thus, it is possible that a CB 1 -like rather than the CB 1 receptor (presumably the only receptor of the two that ⌬ 9 -THC activates) is responsible for the beneficial effects of other cannabinoids in Parkinson's disease. On the other hand, the therapeutic value of CB 1 receptor antagonists in Huntington's disease (van der Stelt and Di Marzo, 2003) can be better explained by the findings of our study (i.e., by the simultaneous facilitation of GABAergic transmission and CB 1 receptor-independent inhibition of glutamate release that could brake the glutamatergic excitotoxicity).
In summary, cannabinoids can modulate motor function via direct inhibition of striatal GABA and glutamate release. Moreover, the demonstration of a pharmacologically fully CB 1 -like effect in the CB 1 Ϫ/Ϫ mice indicates that the conventional cannabinoid ligands, routinely used to identify CB 1 receptors, might be inadequate and should provoke a systemic reevaluation using CB 1 -deficient mice of previous results based solely on the pharmacological identification of the CB 1 receptor.
